# Stem Cell Factor Medication for Aplastic Anemia

> **NCT00001398** · PHASE1 · COMPLETED · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 40 (—)

## Conditions studied

- Aplastic Anemia
- Pancytopenia

## Interventions

- **DRUG:** Recombinant Methionyl Human Stem Cell Factor (r-metHuSCF)

## Key facts

- **NCT ID:** NCT00001398
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1993-10
- **Primary completion:** —
- **Final completion:** 2002-06
- **Target enrollment:** 40 (—)
- **Last updated:** 2008-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00001398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00001398, "Stem Cell Factor Medication for Aplastic Anemia". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00001398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*